April 8, 2022
Scientific poster AACR 2022
Development of an Adaptable Drug Affinity Conjugate, targeting the CD40 protein, provides a flexible therapeutic peptide cargo delivery to dendritic (APC) cells
CD40 agonistic antibodies targeting antigen-presenting cells (APCs) rely on simultaneous presentation of an antigen for optimal efficacy since the co-stimulatory signal alone will not lead to T-cell activation. The ADAC technology platform utilizes a high-affinity interaction between a short non-immunogenic peptide-tag (pTag) and a single-chain fragment (scFv) of the antibody to enable attachment of the peptide cargo.
This poster demonstrates the ability of a novel Adaptable Drug Affinity Conjugate (ADAC) – a refinement of the traditional Antibody Drug Conjugate (ADC) approach – to improve peptide stability, while retaining agonistic activity and providing superior T-cell activation and expansion.
This first-in-class delivery strategy using ADAC technology meets demands for a flexible peptide cargo delivery, ensuring in vivo T-cell priming via a CD40- targeted approach. Simultaneous immune activation and peptide presentation can ensure optimal drug efficacy and safety.
Please contact our Chief Scientific Officer, Associate Professor Sara Mangsbo, if you would like more information.